Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.59
+0.47 (+0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
55
56
Next >
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
November 09, 2022
Via
Benzinga
Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022
November 09, 2022
On CNBC's "Options Action," Michael Khouw of Optimize Advisors said that AstraZeneca plc. (NASDAQ: AZN) traded 3.9 times its average daily put volume on Tuesday.
Via
Benzinga
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
November 09, 2022
From
AstraZeneca
Via
Business Wire
Why Are Apellis Pharmaceuticals Shares Falling Today?
November 04, 2022
Via
Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
November 04, 2022
Via
Benzinga
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
November 02, 2022
The company released encouraging year-end guidance.
Via
The Motley Fool
AstraZeneca's Imfinzi Combo Scores FDA Approval For Liver Cancer
October 24, 2022
Via
Benzinga
Sorrento Has Potential To Deliver Multiple Best-In-Class Products
November 02, 2022
Via
Benzinga
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
November 01, 2022
As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends.
Via
InvestorPlace
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine
November 01, 2022
Via
Benzinga
15 Global Psychedelics Executives To Keep An Eye On In 2022
October 28, 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...
Via
Benzinga
Why Invitae Stock Was So Healthy This Week
October 28, 2022
Even though the genetics testing specialist didn't divulge the financial details of a new partnership, investors nevertheless were happpy about the news.
Via
The Motley Fool
Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest
October 28, 2022
Although "Big Tech" is currently struggling, but there are still many good top tech stocks to buy at this point.
Via
InvestorPlace
3 Perfect Stocks Retirees Can Buy Hand Over Fist Right Now
October 28, 2022
Bargains abound for seniors who want steady long-term appreciation potential.
Via
The Motley Fool
AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord
October 27, 2022
Via
Benzinga
A New BioTech Research Race Is Focused On Improving Life For MS Patients
October 27, 2022
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is...
Via
Benzinga
ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
October 27, 2022
From
Alexion
Via
Business Wire
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
October 27, 2022
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all...
Via
MarketBeat
Intel's Self-Driving Tech Firm Raises Over $800M In IPO, Alphabet Misses Q3 Earnings Expectations, Lyft Cuts Price For Monthly Subscription Plan: Top Stories Wednesday, Oct. 26
October 26, 2022
Benzinga
Via
Benzinga
AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings
October 26, 2022
Via
Benzinga
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
October 26, 2022
From
AstraZeneca
Via
Business Wire
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
October 26, 2022
From
AstraZeneca
Via
Business Wire
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
October 25, 2022
The company hopes to come out next year with at least one heart-failure drug.
Via
Investor's Business Daily
Twitter Considers Crypto Wallet, Geopolitical Woes To Keep Tesla Shares Volatile, Juul Explores Possible Bailout: Top Stories Tuesday, Oct. 25
October 25, 2022
Benzinga
Via
Benzinga
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
October 25, 2022
Biosimilars are bringing down prescription drug costs without sacrificing quality.
Via
The Motley Fool
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
October 25, 2022
Via
Benzinga
US Stock Futures Down; Big Tech Earnings In Focus
October 25, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the...
Via
Benzinga
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
October 24, 2022
From
AstraZeneca
Via
Business Wire
US Stock Futures Lower Following Friday's Rally; Tesla In Focus
October 24, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the...
Via
Benzinga
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.